Role of L2 cysteines in papillomavirus infection and neutralization

Ratish Gambhira, Subhashini Jagu, Balasubramanyam Karanam, Patricia M. Day, Richard S Roden

Research output: Contribution to journalArticle

Abstract

Vaccination of mice with minor capsid protein L2 or passive transfer with the L2-specific neutralizing monoclonal antibody RG-1 protects against human papillomavirus type 16 (HPV16) challenge. Here we explored the nature of the RG-1 epitope and its contribution to viral infectivity. RG-1 bound equivalently HPV16 L2 residues 17-36 with or without an intact C22-C28 disulphide bridge. HPV16 L2 mutations K20A, C22A, C22S, C28A, C28S, or P29A prevented RG-1 binding, whereas Y19A, K23A or Q24A had no impact. Mutation of either C22 or C28 to alanine or serine compromises HPV16 pseudoviral infectivity both in vitro and in the murine vaginal tract, but does not impact pseudovirion assembly. Despite their lack of infectivity, HPV16 pseudovirions containing C22S or C28S mutant L2 bind to cell surfaces, are taken up, and expose the 17-36 region on the virion surface as for wild type HPV16 pseudovirions suggesting normal furin cleavage of L2. Mutation of the second cysteine residue in Bovine papillomavirus type 1 (BPV1) L2 to serine (C25S) dramatically reduced the infectivity of BPV1 pseudovirions. Surprisingly, in contrast to the double mutation in HPV16 L2, the BPV1 L2 C19S, C25S double mutation reduced BPV1 pseudovirion infectivity of 293TT cells by only half.

Original languageEnglish (US)
Article number176
JournalVirology Journal
Volume6
DOIs
StatePublished - 2009

Fingerprint

Papillomavirus Infections
Human papillomavirus 16
Cysteine
Bovine papillomavirus 1
Mutation
Serine
Furin
Capsid Proteins
Neutralizing Antibodies
Disulfides
Alanine
Virion
Epitopes
Vaccination
Monoclonal Antibodies

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Role of L2 cysteines in papillomavirus infection and neutralization. / Gambhira, Ratish; Jagu, Subhashini; Karanam, Balasubramanyam; Day, Patricia M.; Roden, Richard S.

In: Virology Journal, Vol. 6, 176, 2009.

Research output: Contribution to journalArticle

Gambhira, Ratish ; Jagu, Subhashini ; Karanam, Balasubramanyam ; Day, Patricia M. ; Roden, Richard S. / Role of L2 cysteines in papillomavirus infection and neutralization. In: Virology Journal. 2009 ; Vol. 6.
@article{d3e708ef2b1a48abb79d3436f0ee8ff9,
title = "Role of L2 cysteines in papillomavirus infection and neutralization",
abstract = "Vaccination of mice with minor capsid protein L2 or passive transfer with the L2-specific neutralizing monoclonal antibody RG-1 protects against human papillomavirus type 16 (HPV16) challenge. Here we explored the nature of the RG-1 epitope and its contribution to viral infectivity. RG-1 bound equivalently HPV16 L2 residues 17-36 with or without an intact C22-C28 disulphide bridge. HPV16 L2 mutations K20A, C22A, C22S, C28A, C28S, or P29A prevented RG-1 binding, whereas Y19A, K23A or Q24A had no impact. Mutation of either C22 or C28 to alanine or serine compromises HPV16 pseudoviral infectivity both in vitro and in the murine vaginal tract, but does not impact pseudovirion assembly. Despite their lack of infectivity, HPV16 pseudovirions containing C22S or C28S mutant L2 bind to cell surfaces, are taken up, and expose the 17-36 region on the virion surface as for wild type HPV16 pseudovirions suggesting normal furin cleavage of L2. Mutation of the second cysteine residue in Bovine papillomavirus type 1 (BPV1) L2 to serine (C25S) dramatically reduced the infectivity of BPV1 pseudovirions. Surprisingly, in contrast to the double mutation in HPV16 L2, the BPV1 L2 C19S, C25S double mutation reduced BPV1 pseudovirion infectivity of 293TT cells by only half.",
author = "Ratish Gambhira and Subhashini Jagu and Balasubramanyam Karanam and Day, {Patricia M.} and Roden, {Richard S}",
year = "2009",
doi = "10.1186/1743-422X-6-176",
language = "English (US)",
volume = "6",
journal = "Virology Journal",
issn = "1743-422X",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Role of L2 cysteines in papillomavirus infection and neutralization

AU - Gambhira, Ratish

AU - Jagu, Subhashini

AU - Karanam, Balasubramanyam

AU - Day, Patricia M.

AU - Roden, Richard S

PY - 2009

Y1 - 2009

N2 - Vaccination of mice with minor capsid protein L2 or passive transfer with the L2-specific neutralizing monoclonal antibody RG-1 protects against human papillomavirus type 16 (HPV16) challenge. Here we explored the nature of the RG-1 epitope and its contribution to viral infectivity. RG-1 bound equivalently HPV16 L2 residues 17-36 with or without an intact C22-C28 disulphide bridge. HPV16 L2 mutations K20A, C22A, C22S, C28A, C28S, or P29A prevented RG-1 binding, whereas Y19A, K23A or Q24A had no impact. Mutation of either C22 or C28 to alanine or serine compromises HPV16 pseudoviral infectivity both in vitro and in the murine vaginal tract, but does not impact pseudovirion assembly. Despite their lack of infectivity, HPV16 pseudovirions containing C22S or C28S mutant L2 bind to cell surfaces, are taken up, and expose the 17-36 region on the virion surface as for wild type HPV16 pseudovirions suggesting normal furin cleavage of L2. Mutation of the second cysteine residue in Bovine papillomavirus type 1 (BPV1) L2 to serine (C25S) dramatically reduced the infectivity of BPV1 pseudovirions. Surprisingly, in contrast to the double mutation in HPV16 L2, the BPV1 L2 C19S, C25S double mutation reduced BPV1 pseudovirion infectivity of 293TT cells by only half.

AB - Vaccination of mice with minor capsid protein L2 or passive transfer with the L2-specific neutralizing monoclonal antibody RG-1 protects against human papillomavirus type 16 (HPV16) challenge. Here we explored the nature of the RG-1 epitope and its contribution to viral infectivity. RG-1 bound equivalently HPV16 L2 residues 17-36 with or without an intact C22-C28 disulphide bridge. HPV16 L2 mutations K20A, C22A, C22S, C28A, C28S, or P29A prevented RG-1 binding, whereas Y19A, K23A or Q24A had no impact. Mutation of either C22 or C28 to alanine or serine compromises HPV16 pseudoviral infectivity both in vitro and in the murine vaginal tract, but does not impact pseudovirion assembly. Despite their lack of infectivity, HPV16 pseudovirions containing C22S or C28S mutant L2 bind to cell surfaces, are taken up, and expose the 17-36 region on the virion surface as for wild type HPV16 pseudovirions suggesting normal furin cleavage of L2. Mutation of the second cysteine residue in Bovine papillomavirus type 1 (BPV1) L2 to serine (C25S) dramatically reduced the infectivity of BPV1 pseudovirions. Surprisingly, in contrast to the double mutation in HPV16 L2, the BPV1 L2 C19S, C25S double mutation reduced BPV1 pseudovirion infectivity of 293TT cells by only half.

UR - http://www.scopus.com/inward/record.url?scp=72449124661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449124661&partnerID=8YFLogxK

U2 - 10.1186/1743-422X-6-176

DO - 10.1186/1743-422X-6-176

M3 - Article

C2 - 19860897

AN - SCOPUS:72449124661

VL - 6

JO - Virology Journal

JF - Virology Journal

SN - 1743-422X

M1 - 176

ER -